



**PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: D. J. Madar, et al.

Serial No.: 10/659,860

Filed: September 11, 2003

For: Pharmaceutical Compositions as Inhibitors of
Dipeptidyl Peptidase-IV (DPP-IV)

Examiner: (Not assigned yet)

Group Art Unit: 1614

Case No.: 6979.US.O2

Date: April 6, 2004

Certificate of Mailing under 37 CFR §1.8(a):
I hereby certify that this paper (along with any
paper referred to as being attached or
enclosed) is being deposited with the United
States Postal Service with sufficient postage
as First Class Mail addressed to:

Mail Stop: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date of Deposit: April 19, 2004

Wanda C. Smith 4/19/04
Wanda E. Smith

Date

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is the Information Disclosure Statement of
D. J. Madar, et al., for Pharmaceutical Compositions as Inhibitors of Dipeptidyl
Peptidase-IV (DPP-IV), filed September 19, 2002.

Also enclosed are: USPTO Form 1449 - 1 page (in duplicate)
Copy of eight (8) references with one translation
Return-receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees
required under 37 CFR 1.16, as well as any patent application processing fees under
37 CFR 1.17 associated with this communication for which full payment had not been
tendered, to Deposit Account No. 01-0025. **A duplicate copy of this sheet is
enclosed.**



23492


ABBOTT LABORATORIES

Telephone: (847) 936-3362

Facsimile: (847) 938-2623

Respectfully submitted,

D. J. Madar, et al.


Christopher P. Rogers
Registration No. 36,334
Attorney for Applicants



**PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: D. J. Madar, et al.

Serial No.: 10/659,860

Filed: September 11, 2003

For: Pharmaceutical Compositions as Inhibitors of
Dipeptidyl Peptidase-IV (DPP-IV)

Examiner: (Not assigned yet)

Group Art Unit: 1614

Case No.: 6979.US.O2

Date: April 6, 2004

Certificate of Mailing under 37 CFR §1.8(a):
I hereby certify that this paper (along with any
paper referred to as being attached or
enclosed) is being deposited with the United
States Postal Service with sufficient postage
as First Class Mail addressed to:

Mail Stop: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date of Deposit: April 19, 2004

Wanda C. Smith

Wanda E. Smith

Date

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The following information is submitted pursuant to 37 C.F.R. §§ 1.97 and 1.98 in accordance with applicants' duty of disclosure under 37 C.F.R. §1.56. This submission is not an admission that the documents cited herein are prior art as to the invention claimed.

The references submitted are listed on the attached Form PTO-1449, and a copy of each is enclosed. Review is respectfully requested, and the Examiner is asked to place his/her initials next to each reference listed on the form to indicate that the reference was considered.

Because this Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits of the application, it is believed that under 37 C.F.R. §1.97(b), no fee is due in connection herewith.



23492

ABBOTT LABORATORIES
Telephone: (847) 936-3362
Facsimile: (847) 938-2623

Respectfully submitted,

D. J. Madar, et al.

Christopher P. Rogers
Registration No. 36,334
Attorney for Applicants

DATE: April 7, 2004

SHEET _1_ of _1_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
 (Modified) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT
 (Use several sheets if necessary)
 (Under 37 CFR 1.98 (b))

ATTY. DOCKET NO.	SERIAL NO.
6979.USO2	10/659,960
APPLICANT	
D. J. Madar, et al.	
FILING DATE	GROUP
9/11/03	1614

U.S.PATENT DOCUMENTS

Examiner Initials	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
A1	6,395,767	05/28/02	Robl, et al.			
A2	6,011,155	01/04/02	Villhauer			
A3						
A4						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
B1		01/34594	17.05.2001	WO				
B2		01/68603	20.09.2001	WO				
B3		04/016587	26.02.04	WO (translation included)			X	

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Ahren, B., "Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control over a 4-Week Study Period in Type 2 Diabetes", Diabetes Care, Vol. 25, No. 5, May 2002, pp 869-875
C2	Deacon, C. F., "Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig", Diabetes, Vol. 47, May 1998, pp 764-769
C3	Ohnuma, K., "Soluble CD26/Dipeptidyl Peptidase IV Induces T Cell Proliferation through CD86 Up-Regulation on APCs ¹ ", J. of Immunology, Vol. 167, No. 12, 2001, pp 6745-6755

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)